Unlocking the Potential of Loxl2: A Review on the Potential Drug Target and Biomarker

Target Name: LOXL2

NCBI ID: G4017

LOXL2

Unlocking the Potential of Loxl2: A Review on the Potential Drug Target and Biomarker

Introduction

Loxl2, a protein known as WS9-14, is a non-coding RNA molecule that is expressed in various tissues and cells of the human body. Loxl2 plays a critical role in the regulation of cell proliferation, apoptosis, and metabolism. Its unique structure and function make it an attractive target for drug development and research. In this article, we will explore the potential of Loxl2 as a drug target and biomarker.

Potential Drug Target

The potential drug targets of Loxl2 are numerous and diverse. Loxl2 has been shown to play a role in various cellular processes, including cell growth, apoptosis, and transcriptional regulation. It has been shown to interact with numerous protein molecules, including p53, beetle Toxin (pestide) A (PA), histone (histone H3K9me3), and RNA binding protein (RBP), etc.

One of the most promising potential drug targets of Loxl2 is its role in cancer. Loxl2 has been shown to be highly expressed in various types of cancer, including breast, lung, and ovarian cancer. It has also been shown to be involved in the regulation of cell cycle progression and the maintenance of the pro-tumorigenic state. Therefore, Loxl2 may be an attractive target for anti-cancer drugs that target the regulation of cell cycle progression and apoptosis.

Another potential drug target of Loxl2 is its role in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Loxl2 has been shown to play a role in the regulation of neurogenesis, synaptic plasticity, and neuroprotection. Therefore, Loxl2 may be an attractive target for neurodegenerative diseases that target the regulation of neurogenesis and synaptic plasticity.

Potential Biomarkers

Loxl2 has also been shown to be a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Loxl2 has also been shown to be involved in the regulation of cell proliferation, apoptosis, and metabolism, which may be useful as biomarkers for various diseases.

In cancer, Loxl2 has been shown to be involved in the regulation of cell cycle progression, apoptosis, and metastasis. Therefore, Loxl2 may be an attractive biomarker for various types of cancer, including breast, lung, and ovarian cancer.

In neurodegenerative diseases, Loxl2 has been shown to play a role in the regulation of neurogenesis, synaptic plasticity, and neuroprotection. Therefore, Loxl2 may be an attractive biomarker for neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In autoimmune diseases, Loxl2 has been shown to play a role in the regulation of immune cell function and inflammation. Therefore, Loxl2 may be an attractive biomarker for autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis.

Conclusion

In conclusion, Loxl2 is an attractive protein that has the potential to be a drug target and biomarker. Its unique structure and function make it an attractive target for drug development and research. Further studies are needed to fully understand the role of Loxl2 in various cellular processes and its potential as a drug target and biomarker.

Protein Name: Lysyl Oxidase Like 2

Functions: Mediates the post-translational oxidative deamination of lysine residues on target proteins leading to the formation of deaminated lysine (allysine) (PubMed:27735137). Acts as a transcription corepressor and specifically mediates deamination of trimethylated 'Lys-4' of histone H3 (H3K4me3), a specific tag for epigenetic transcriptional activation (PubMed:27735137). Shows no activity against histone H3 when it is trimethylated on 'Lys-9' (H3K9me3) or 'Lys-27' (H3K27me3) or when 'Lys-4' is monomethylated (H3K4me1) or dimethylated (H3K4me2) (PubMed:27735137). Also mediates deamination of methylated TAF10, a member of the transcription factor IID (TFIID) complex, which induces release of TAF10 from promoters, leading to inhibition of TFIID-dependent transcription (PubMed:25959397). LOXL2-mediated deamination of TAF10 results in transcriptional repression of genes required for embryonic stem cell pluripotency including POU5F1/OCT4, NANOG, KLF4 and SOX2 (By similarity). Involved in epithelial to mesenchymal transition (EMT) via interaction with SNAI1 and participates in repression of E-cadherin CDH1, probably by mediating deamination of histone H3 (PubMed:16096638, PubMed:27735137, PubMed:24414204). During EMT, involved with SNAI1 in negatively regulating pericentromeric heterochromatin transcription (PubMed:24239292). SNAI1 recruits LOXL2 to pericentromeric regions to oxidize histone H3 and repress transcription which leads to release of heterochromatin component CBX5/HP1A, enabling chromatin reorganization and acquisition of mesenchymal traits (PubMed:24239292). Interacts with the endoplasmic reticulum protein HSPA5 which activates the IRE1-XBP1 pathway of the unfolded protein response, leading to expression of several transcription factors involved in EMT and subsequent EMT induction (PubMed:28332555). Involved in E-cadherin repression following hypoxia, a hallmark of EMT believed to amplify tumor aggressiveness, suggesting that it may play a role in tumor progression (PubMed:20026874). When secreted into the extracellular matrix, promotes cross-linking of extracellular matrix proteins by mediating oxidative deamination of peptidyl lysine residues in precursors to fibrous collagen and elastin (PubMed:20306300). Acts as a regulator of sprouting angiogenesis, probably via collagen IV scaffolding (PubMed:21835952). Acts as a regulator of chondrocyte differentiation, probably by regulating expression of factors that control chondrocyte differentiation (By similarity)

The "LOXL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOXL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets